Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Tecnología para la monitorización y control de Diabetes

Resultados 119 resultados
LastUpdate Última actualización 10/02/2026 [06:57:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
Resultados 1 a 25 de 119 nextPage  

FLUID DELIVERY DEVICE HAVING MULTIPLE PENETRATING ELEMENTS

NºPublicación:  US20260034298A1 05/02/2026
Solicitante: 
INSULET CORP [US]
INSULET CORPORATION
US_20260034298_PA

Resumen de: US20260034298A1

Methods and apparatuses for performing an insertion process for a plurality of penetrating elements are described. For example, a wearable fluid infusion device may include a cannula and/or needle for infusing a fluid into a patient and a sensor for sensing a physical characteristic of the patient. A non-limiting example of a fluid may be or may include insulin. An illustrative and non-restrictive example of a physical characteristic may include a blood glucose level. The wearable infusion device may be configured to facilitate insertion of the multiple penetrating elements, such as a cannula and a sensor, in a single simultaneous insertion step instead of requiring individual insertion steps for each of multiple penetrating elements. Other embodiments are described.

DETERMINING A CONCENTRATION OF GLUCOSE IN A SUBJECT'S BLOOD

NºPublicación:  AU2024313070A1 05/02/2026
Solicitante: 
AFON TECH LTD
AFON TECHNOLOGY LTD
AU_2024313070_PA

Resumen de: AU2024313070A1

According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising: acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject; acquiring (204) second measurement data indicative of at least one parameter associated with the subject; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.

DETERMINING A CONCENTRATION OF GLUCOSE IN A SUBJECT'S BLOOD

NºPublicación:  AU2024312680A1 05/02/2026
Solicitante: 
AFON TECH LTD
AFON TECHNOLOGY LTD
AU_2024312680_PA

Resumen de: AU2024312680A1

According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject, the EM signal having been emitted from a device in contact with the body part of the subject; acquiring (204) second measurement data indicative of a pressure applied to the body part of the subject by the device; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.

METHOD AND SYSTEM FOR GLYCEMIC PREDICTION AND DYNAMIC VISUALIZATION

NºPublicación:  US20260033753A1 05/02/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc
US_20260033753_PA

Resumen de: US20260033753A1

Disclosed herein are system, method, and computer program product embodiments for interconnecting a prediction visualization with user medical data for analyzing the impact of personal choices on future glucose levels. The prediction visualization is configured to generate predictions of glycemic impact based one or more inputs including choices involving diet and exercise and user medical data, such as the user's historical and current glucose levels. The prediction visualization is configured to be adjustable based on user input and the visualization is configured to dynamically update based on user input. The disclosed interface allows the user to adjust the sequencing of these decisions and portion sizes of meal choices and immediately generate new visualizations representing the impact on predicted future glucose levels.

BASAL RATE TESTING USING FREQUENT BLOOD GLUCOSE INPUT

NºPublicación:  US20260034300A1 05/02/2026
Solicitante: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc
US_20260034300_PA

Resumen de: US20260034300A1

An apparatus comprising a user interface configured to generate an electrical signal to start a basal insulin rate test when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration during delivery of insulin according to a specified basal insulin rate pattern, and a controller communicatively coupled to the input and the user interface. The controller includes an insulin calculation module configured for determining at least one of an amount of basal insulin over-delivered and an amount of basal insulin under-delivered during the basal insulin rate test in trying to meet a target blood glucose baseline. Other devices and methods are disclosed.

METHODS, SYSTEMS, AND DEVICES FOR SENSOR FUSION

NºPublicación:  US20260033751A1 05/02/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
US_20260033751_PA

Resumen de: US20260033751A1

A fused sensor glucose value may be calculated based on respective sensor glucose values of a plurality of redundant working electrodes (WEs) of a glucose sensor. A respective resistance value (e.g., membrane resistance (Rmem) and respective calibration value (e.g., a calibration factor (CF) value) may be calculated for each redundant WE, and a respective fusion weight may be calculated for each redundant WE based on the respective resistance and calibration values. A fused sensor glucose value may be calculated based on the respective fusion weight and sensor glucose value of each of the plurality of redundant WEs.

ELECTRONIC DEVICE FOR BLOOD GLUCOSE MEASUREMENT USING DISTRIBUTED FEEDBACK LASER DIODE

NºPublicación:  WO2026029574A1 05/02/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
HANA OPTRONICS INC [KR]
\uC0BC\uC131\uC804\uC790\uC8FC\uC2DD\uD68C\uC0AC,
\uD558\uB098\uC635\uD2B8\uB85C\uB2C9\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC
WO_2026029574_PA

Resumen de: WO2026029574A1

Disclosed is a non-invasive electronic device for blood glucose measurement using a laser array including a plurality of wavelength bands formed in a distributed feedback laser diode. The non-invasive electronic device for blood glucose measurement comprises: a light source unit for forming light including a plurality of wavelength bands; a light reflection unit for reflecting the light to change a travel path of the light to the vertical direction; and a light detection unit for receiving reflected light in which the light traveling after being reflected by the light reflection unit is incident on a user's skin and then reflected, and converting same into an electrical signal.

State-based methods and systems using continuous glucose monitors and accelerometers to regulate glucose levels

NºPublicación:  US12539058B1 03/02/2026
Solicitante: 
OPTUM LABS LLC [US]
Optum Labs, LLC
US_12539058_PA

Resumen de: US12539058B1

Embodiments include methods and systems for regulating a user's glucose levels. Systems comprise a processing unit in communication with a glucose monitor, an accelerometer, and a user interface. The glucose monitor generates glucose readings corresponding to the user's glucose levels and the accelerometer generates acceleration readings corresponding to the user's activity. The processing unit determines if the glucose readings indicate a glucose state and whether the acceleration readings indicate an activity state. If the glucose state and the activity state coincide, the processing unit sends a message to the user interface recommending a behavior that would influence the user's glucose level. Methods comprise determining, at a processing unit, if glucose readings indicate a glucose state, if acceleration readings indicate an activity state, whether the glucose state and activity state coincide and, if so, sending a message to a user interface recommending a behavior that would influence the user's glucose level.

ELECTRONIC CIRCUIT AND ANALYTE SENSOR SYSTEM SUCH AS A GLUCOSE SENSOR SYSTEM AND METHOD OF OPERATING AN ANALYTE SENSOR AND SYSTEM

NºPublicación:  PL4223220T3 02/02/2026
Solicitante: 
F HOFFMANN LA ROCHE AG [CH]
F. Hoffmann-La Roche AG
PL_4223220_T3

Resumen de: CA3247818A1

The invention refers to an electronic circuit configured to operate an analyte sensor, such as a glucose sensor, the circuit having at least a first and a second electrical connection configured to be connected to a first and a second electrode of the analyte sensor respectively, wherein the electronic circuit has a voltage source and a common potential conductor section electrically provided on a potential of a pole of the voltage source, wherein with the voltage source an electric potential different to the potential of the common potential conductor section can be provided to the first electrical connection; and wherein the second electrical connection is connected to the common potential conductor section through one or more common potential connection paths and wherein none of the common potential connection paths connects the second electrical connection to the common potential conductor section through fewer than three or more series-connected electronic components.

EXERCISE MONITORING AND REMINDING DEVICE FOR DIABETIC CARDIOMYOPATHY PATIENTS

NºPublicación:  LU602751B1 02/02/2026
Solicitante: 
LU WEIFANG [CN]
ZHAI YUE [CN]
JIAMUSI UNIV HONGDA HOSPITAL CO LTD [CN]
LIU YING [CN]
LU Weifang,
ZHAI Yue,
JIAMUSI UNIVERSITY HONGDA HOSPITAL CO., LTD,
LIU Ying
LU_602751_PA

Resumen de: LU602751B1

The present invention provides an exercise monitoring and reminding device for diabetic cardiomyopathy patients, including a blood glucose monitor with a pricking needle. The pricking needle is connected to the skin of a patient’s arm. The device includes a data receiver, attached and connected to the blood glucose monitor. An exercise monitoring ring is mounted on the data receiver. A manual tightening mechanism is arranged, effectively controlling the exercise monitoring ring to form a cooperation, nesting the blood glucose monitor, identifying blood glucose detection data, and combining it with exercise data. Waste in the blood glucose monitor use is avoided. Through the cooperation of a primary strap, a connecting buckle, an auxiliary strap and a tightener, it effectively forms manual tightening use, improves the positioning of the exercise monitoring ring on the arm for monitoring, and cooperates with components on the tightener to form different forms of exercise reminders.

CONTINUOUS ANALYTE MONITORING SYSTEM WITH MICRONEEDLE ARRAY

NºPublicación:  US20260026749A1 29/01/2026
Solicitante: 
BIOLINQ INCORPORATED [US]
Biolinq Incorporated
US_20260026749_PA

Resumen de: US20260026749A1

Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.

SYSTEMS AND METHODS FOR TITRATING A BASAL INSULIN DOSE AND FOR DETECTING NON-COMPLIANCE WITH DOSE RECOMMENDATIONS

NºPublicación:  WO2026025065A2 29/01/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
ABBOTT DIABETES CARE INC
WO_2026025065_PA

Resumen de: WO2026025065A2

A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.

Medicine injection and disease management systems, devices, and methods

NºPublicación:  AU2026200109A1 29/01/2026
Solicitante: 
BIGFOOT BIOMEDICAL INC
Bigfoot Biomedical, Inc
AU_2026200109_A1

Resumen de: AU2026200109A1

There is disclosed a cap for an insulin pen comprising: one or more sensors adapted to detect a position of a plunger within an insulin pen; and a user interface comprising one or more user-selectable icons or buttons adapted to announce a meal or an intent to have a meal. have a meal. an a n h a v e a m e a l

SYSTEMS AND METHODS FOR PREDICTING BLOOD GLUCOSE

NºPublicación:  WO2026025081A1 29/01/2026
Solicitante: 
CEDARS SINAI MEDICAL CENTER [US]
CEDARS-SINAI MEDICAL CENTER
WO_2026025081_PA

Resumen de: WO2026025081A1

A method for predicting a blood glucose or blood glucose condition in an individual. The method includes receiving, at a current time, data associated with the individual, the data including (i) a set of one or more static data points each being generated or collected at an identical prior point in time occurring before the current time, and (ii) a series of sequential data points, each of the sequential data points being generated or collected within a prior window of time occurring before the current time; inputting the data associated with the individual into a model; and receiving from the model an indication of a risk of the individual developing hypoglycemia within a subsequent window of time after the current time.

ELECTRONIC DEVICE, AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT METHOD OF ELECTRONIC DEVICE

NºPublicación:  WO2026023864A1 29/01/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
HANA OPTRONICS INC [KR]
\uC0BC\uC131\uC804\uC790 \uC8FC\uC2DD\uD68C\uC0AC,
\uD558\uB098\uC635\uD2B8\uB85C\uB2C9\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC
WO_2026023864_PA

Resumen de: WO2026023864A1

In an electronic device and an operation method of the electronic device, according to one embodiment, the electronic device may comprise: a light source unit for generating lights of a plurality of wavelength bands; an optical body for irradiating the lights of the plurality of wavelength bands onto the skin of a user; a light-receiving unit for detecting light obtained by reflecting the lights of the plurality of wavelength bands from the skin of the user; a memory for storing at least one computer program including instructions; and at least one processor. When individually or collectively executed by the at least one processor, the instructions can instruct the electronic device to: acquire the intensity of irradiation light of a specific wavelength band irradiated from the light source unit at the user and the intensity of reflected light obtained by reflecting the irradiation light of the specific wavelength band from the user; calculate the response gain of the irradiation light of the specific wavelength band on the basis of the ratio of the intensity of the irradiation light to the intensity of the reflected light; and identify a blood glucose level corresponding to the calculated response gain by using a blood glucose level database including blood glucose level information corresponding to the response gain of each of irradiation lights of the plurality of wavelength bands.

MAGNET SYSTEM FOR NUCLEAR MAGNETIC RESONANCE

NºPublicación:  WO2026024763A1 29/01/2026
Solicitante: 
SYNEX MEDICAL INC [CA]
CLOCKER KYLE [US]
SYNEX MEDICAL INC,
CLOCKER, Kyle
WO_2026024763_PA

Resumen de: WO2026024763A1

The system can include: an array of magnets. In variants, the system can function to generate a homogenous magnetic field within a sample (e.g., in the pulp of a finger). In an example, the system can be used for nuclear magnetic resonance (NMR) imaging and/or magnetic resonance imaging (MRI). In a specific example, the system can be used to measure blood analyte levels (e.g., glucose levels) within a sample.

BLOOD GLUCOSE MEASUREMENT DEVICE USING PHOTONICS MODULE

NºPublicación:  WO2026024081A1 29/01/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
HANA OPTRONICS INC [KR]
\uC0BC\uC131\uC804\uC790 \uC8FC\uC2DD\uD68C\uC0AC,
\uD558\uB098\uC635\uD2B8\uB85C\uB2C9\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC
WO_2026024081_PA

Resumen de: WO2026024081A1

According to one embodiment of the present disclosure, an electronic device may comprise: a substrate; a plurality of light sources disposed on the substrate and radiating light of different wavelengths; a temperature sensor disposed close to the plurality of light sources; a wavelength detection circuit electrically connected to at least two light sources among the plurality of light sources; a memory storing instructions; and a processor. The instructions, when executed by the processor, may cause the electronic device to acquire temperature information related to the plurality of light sources by using the temperature sensor. The instructions, when executed by the processor, may cause the electronic device to measure the amount of change in wavelength between the plurality of light sources by using the wavelength detection circuit. The instructions, when executed by the processor, may cause the electronic device to adjust the amount of change in wavelength to be less than or equal to a reference amount of change in wavelength when the amount of change in wavelength according to the acquired temperature information exceeds the reference amount of change in wavelength. The instructions, when executed by the processor, may cause the electronic device to supply a current corresponding to the adjusted amount of change in wavelength to the plurality of light sources. In addition to various embodiments disclosed in the present document, other various embodiments may be possible.

DISPOSABLE MULTI-DOSE HIGH-PRECISION INSULIN INJECTION APPARATUS

NºPublicación:  WO2026020518A1 29/01/2026
Solicitante: 
ESC MEDTECH SUZHOU CO LTD [CN]
\u6613\u5B89\u9002\u533B\u7597\u79D1\u6280\uFF08\u82CF\u5DDE\uFF09\u6709\u9650\u516C\u53F8
WO_2026020518_PA

Resumen de: WO2026020518A1

Disclosed is a disposable multi-dose high-precision insulin injection apparatus, comprising a housing, and a dose adjustment unit and an injection transmission unit that are arranged in the housing. The dose adjustment unit is arranged in the upper part in the housing, and the injection transmission unit is arranged in the lower part in the housing. A dose setting unit is in transmission connection with the injection transmission unit. The dose adjustment unit is used for presetting an injection dose, and the injection transmission unit is used for transmitting injection power and discharging the preset injection dose to complete an injection. The disposable multi-dose high-precision insulin injection apparatus described in the present invention uses the dose setting unit to set a dose of insulin to be injected and uses the injection transmission unit to complete the injection of the corresponding dose. The dose setting unit can accurately set a dose to be injected. The apparatus is simple and convenient to operate and cost-effective.

USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM

NºPublicación:  US20260027301A1 29/01/2026
Solicitante: 
INSULET CORP [US]
INSULET CORPORATION
US_20260027301_PA

Resumen de: US20260027301A1

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

SYSTEMS AND METHODS FOR TITRATING A BASAL INSULIN DOSE AND FOR DETECTING NON-COMPLIANCE WITH DOSE RECOMMENDATIONS

NºPublicación:  US20260026758A1 29/01/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc
US_20260026758_PA

Resumen de: US20260026758A1

A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.

SYSTEM FOR DECISION SUPPORT

NºPublicación:  EP4685812A2 28/01/2026
Solicitante: 
DEXCOM INC [US]
DexCom, Inc
EP_4685812_A2

Resumen de: EP4685812A2

Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.

CONTINUOUS GLUCOSE MONITORING DEVICE

NºPublicación:  HUE073365T2 28/01/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
US_2025352093_PA

Resumen de: US2025352093A1

The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.

CONTINUOUS BLOOD SUGAR MEASURING DEVICE

NºPublicación:  HUE073160T2 28/01/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
US_2025352095_PA

Resumen de: US2025352095A1

The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.

METHOD TO AVOID HYPOGLYCEMIA BY MINIMIZING LATE POST-PRANDIAL INSULIN INFUSION IN AID SYSTEM

NºPublicación:  AU2024343617A1 22/01/2026
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
AU_2024343617_PA

Resumen de: WO2025064417A1

Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

DECISION SUPPORT FOR GLUCOSE-KETONE SENSOR

Nº publicación: AU2024343861A1 22/01/2026

Solicitante:

ABBOTT DIABETES CARE INC
ABBOTT DIABETES CARE INC

AU_2024343861_PA

Resumen de: AU2024343861A1

A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in the bodily fluid of a patient. The application is configured to display at least one of (1) a current ketone level and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time that the ketone levels are above at least one predetermined threshold level. The application is also configured to determine if the current ketone level is above the at least one predetermined threshold level, and in response to determining that the current ketone level is above the at least one predetermined threshold level, output an alarm, wherein the alarm is outputted periodically while the current ketone level is above the at least one predetermined threshold level.

traducir